Key Points
- Insider sale: Medpace President Jesse Geiger sold 31,707 shares on March 17 at an average of $455.30 for proceeds of about $14.44 million, leaving him with 15,000 shares — a 67.88% reduction in his position (SEC filing).
- Quarterly results and outlook: Medpace beat expectations with Q EPS of $4.67 versus $4.18 and revenue of $708.45M (up 32% YoY), and set FY2026 guidance of $16.68–$17.50 EPS.
- Analyst view and stock context: The consensus rating is a "Hold" with an average target of $486.67; the stock trades near $460.92 (50‑day MA $511.94, 200‑day MA $538.00), market cap ≈ $13.08B and a one‑year range of $250.05–$628.92.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) President Jesse Geiger sold 31,707 shares of the firm's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares of the company's stock, valued at $6,829,500. This represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Medpace Stock Performance
NASDAQ MEDP opened at $460.92 on Friday. The stock has a 50 day moving average price of $511.94 and a 200-day moving average price of $538.00. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The company has a market capitalization of $13.08 billion, a P/E ratio of 30.13, a P/E/G ratio of 2.18 and a beta of 1.44.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $708.45 million for the quarter, compared to analysts' expectations of $689.53 million. During the same quarter in the previous year, the business posted $3.67 earnings per share. Medpace's quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on MEDP shares. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a "hold" rating for the company in a research report on Wednesday, February 11th. Royal Bank Of Canada began coverage on shares of Medpace in a report on Tuesday, March 3rd. They issued an "outperform" rating and a $522.00 target price for the company. Mizuho set a $582.00 price target on shares of Medpace in a report on Wednesday, February 11th. Barclays raised shares of Medpace from an "underweight" rating to an "equal weight" rating and set a $500.00 price objective for the company in a research note on Friday, March 6th. Finally, Jefferies Financial Group raised Medpace from a "hold" rating to a "buy" rating and set a $560.00 target price on the stock in a research note on Friday, February 13th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $486.67.
View Our Latest Analysis on Medpace
Hedge Funds Weigh In On Medpace
A number of hedge funds have recently added to or reduced their stakes in MEDP. Quent Capital LLC purchased a new position in shares of Medpace during the third quarter worth approximately $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace in the third quarter valued at approximately $27,000. Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. bought a new position in Medpace in the fourth quarter worth approximately $30,000. Finally, Elyxium Wealth LLC purchased a new position in Medpace during the 4th quarter worth $30,000. 77.98% of the stock is currently owned by institutional investors.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
